Cargando…

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

SIMPLE SUMMARY: Genetic rearrangements of the ROS1 gene account for up to 2% of NSCLC patients who sometimes develop brain metastasis, resulting in poor prognosis. This review discusses the tyrosine kinase inhibitor crizotinib plus updates and preliminary results with the newer generation of tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Angelo, Alberto, Sobhani, Navid, Chapman, Robert, Bagby, Stefan, Bortoletti, Carlotta, Traversini, Mirko, Ferrari, Katia, Voltolini, Luca, Darlow, Jacob, Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694780/ https://www.ncbi.nlm.nih.gov/pubmed/33172113 http://dx.doi.org/10.3390/cancers12113293

Ejemplares similares

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Gastric and colonic metastasis from NSCLC: A very unusual case report
por: Catalano, Martina, et al.
Publicado: (2022)

Advances in anti-BRAF therapies for lung cancer
por: Roviello, Giandomenico, et al.
Publicado: (2021)

p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
por: Sobhani, Navid, et al.
Publicado: (2021)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2019)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
por: Beca, Jaclyn M., et al.
Publicado: (2021)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
por: Shaw, A T, et al.
Publicado: (2019)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
por: Wu, Yi-Long, et al.
Publicado: (2022)

Nanopore-based metagenomic sequencing: a diagnostic tool in respiratory tract infection
por: Chapman, Robert, et al.
Publicado: (2022)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
por: Das, Arabinda, et al.
Publicado: (2015)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jf2lmt0vod36tdb69rev0l24sd